Three major U.S. stock indexes close mixed

Healthy dining brand Sweetgreen, Inc. recently unveiled its expansion blueprint for 2026, projecting a net addition of approximately 15 new restaurant openings that year.

Bloomberg integrates licensed financial data into the blockchain via Kaiko, covering approximately $25 billion in the tokenized market.

Syndax Pharmaceuticals, Inc. announces that patient enrollment has been completed for its Phase II clinical trial of Axatilimab for idiopathic pulmonary fibrosis (IPF).

The latest forecast from biotechnology company Mesoblast Limited shows that its core product Ryoncil is expected to generate full-year net revenue between $110 million and $120 million in fiscal year 2026.